Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE 1

Interventions

tislelizumab 12Capecitabine 8apatinib 5Surgical Procedures, Operative 5Carboplatin 5Oxaliplatin 4Drug Therapy 4Cisplatin 4Paclitaxel 3Immunotherapy 3Bevacizumab 3anlotinib 2Standard of Care 2Radiotherapy 2Radiation 2Methods 2Melphalan 2Low-Level Light Therapy 2Letrozole 2Interleukin-2 2Injections 2Cryotherapy 2zanubrutinib 1trastuzumab deruxtecan 1toripalimab 1sintilimab 1pyrotinib 1pertuzumab 1obinutuzumab 1nedaplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER_GOV × ivarmacitinib × Clear all
NCT07313202 2025-12-31

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

Fujian Cancer Hospital

Phase 2 Not yet recruiting
72 enrolled
Other solid neoplasm

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE

Data powered by HemOnc (CC BY 4.0) Colophon âš¡